作者: Antonino Musolino , Nadia Naldi , Beatrice Bortesi , Debora Pezzuolo , Marzia Capelletti
关键词:
摘要: Purpose The anti–HER-2/neu monoclonal antibody trastuzumab has been shown to engage both activatory (fragment C receptor [FcγR]IIIa; FcγRIIa) and inhibitory (FcγRIIb) receptors FcγR polymorphisms have identified that may affect the antibody-dependent cell-mediated cytotoxicity (ADCC) of natural-killer cells/monocytes. In this study, we tested whether are associated with clinical outcome patients breast cancer who received trastuzumab. Patients Methods Fifty-four consecutive HER-2/neu–amplified receiving plus taxane for metastatic disease were evaluated genotype FcγRIIIa-158 valine(V)/phenylalanine(F), FcγRIIa-131 histidine(H)/arginine(R), FcγRIIb-232 isoleucine(I)/threonine(T) polymorphisms. Trastuzumab-mediated ADCC patients' peripheral blood mononuclear cells (PBMCs) was measured by chromium-51 release using a HER-2/neu–expressing human cell line as target. Controls comprised thirt...